Literature DB >> 21130753

Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1.

Brunella Brunelli1, Elena Del Tordello, Emmanuelle Palumbo, Alessia Biolchi, Stefania Bambini, Maurizio Comanducci, Alessandro Muzzi, Mariagrazia Pizza, Rino Rappuoli, John J Donnelly, Marzia M Giuliani, Davide Serruto.   

Abstract

Factor H binding protein (fHbp), one of the main antigens of new vaccines against serogroup B meningococcus, varies in amino acid sequence and level of expression in different clinical isolates. To evaluate the contribution of amino acid sequence variability to vaccine coverage, we constructed a strain that is susceptible to bactericidal killing only by anti-fHbp antibodies and engineered it to express equal levels of 10 different fHbp sub-variants from a constitutive promoter. Testing of these isogenic strains showed that sera from mice or adult volunteers vaccinated with fHbp variant 1.1 were bactericidal against all sub-variants 1 sequences, however the titer against the most distant sequences were several times lower. Sera from vaccinated infants were more susceptible to amino acid variations and they had lower or no bactericidal activity against the distant sub-variants 1 sequences in comparison with sera from adults given the same vaccines. The low coverage provided by fHbp could be overcome using a multicomponent vaccine. We conclude that fHbp is a very important antigen that induces bactericidal antibodies in animals, adults and infants. However, given its high variability of sequence and expression level, it is unlikely that fHbp alone can provide good protection in infants against the distant amino acid sequence variants and therefore multicomponent vaccines inducing protective immunity also against other antigens are more likely to induce a broad protective immunity in all age groups. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21130753     DOI: 10.1016/j.vaccine.2010.11.064

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Genetic characteristics of Neisseria meningitidis serogroup B strains carried by adolescents living in Milan, Italy: implications for vaccine efficacy.

Authors:  Susanna Esposito; Alberto Zampiero; Leonardo Terranova; Valentina Montinaro; Alessia Scala; Valentina Ansuini; Nicola Principi
Journal:  Hum Vaccin Immunother       Date:  2013-07-23       Impact factor: 3.452

2.  Neisseria meningitidis native outer membrane vesicles containing different lipopolysaccharide glycoforms as adjuvants for meningococcal and nonmeningococcal antigens.

Authors:  Jerry C Nagaputra; Christine S Rollier; Manish Sadarangani; J Claire Hoe; Ojas Hrakesh Mehta; Gunnstein Norheim; Muhammad Saleem; Hannah Chan; Jeremy P Derrick; Ian Feavers; Andrew J Pollard; E Richard Moxon
Journal:  Clin Vaccine Immunol       Date:  2013-12-18

3.  Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates.

Authors:  Jane W Marsh; Kathleen A Shutt; Rolando Pajon; Mary M Tulenko; Stephen Liu; Rosemary A Hollick; Julia A Kiehlbauch; Thomas A Clark; David S Stephens; Kathryn E Arnold; Robert A Myers; Leonard W Mayer; Lee H Harrison
Journal:  Vaccine       Date:  2011-06-24       Impact factor: 3.641

Review 4.  The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens.

Authors:  Davide Serruto; Matthew J Bottomley; Sanjay Ram; Marzia M Giuliani; Rino Rappuoli
Journal:  Vaccine       Date:  2012-05-30       Impact factor: 3.641

5.  Emergence of a new Neisseria meningitidis clonal complex 11 lineage 11.2 clade as an effective urogenital pathogen.

Authors:  Yih-Ling Tzeng; Jose A Bazan; Abigail Norris Turner; Xin Wang; Adam C Retchless; Timothy D Read; Evelyn Toh; David E Nelson; Carlos Del Rio; David S Stephens
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-03       Impact factor: 11.205

6.  Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies.

Authors:  Kate L Seib; Brunella Brunelli; Barbara Brogioni; Emmanuelle Palumbo; Stefania Bambini; Alessandro Muzzi; Federica DiMarcello; Sara Marchi; Arie van der Ende; Beatrice Aricó; Silvana Savino; Maria Scarselli; Maurizio Comanducci; Rino Rappuoli; Marzia M Giuliani; Mariagrazia Pizza
Journal:  Infect Immun       Date:  2010-12-13       Impact factor: 3.441

7.  An analysis of the sequence variability of meningococcal fHbp, NadA and NHBA over a 50-year period in the Netherlands.

Authors:  Stefania Bambini; Jurgen Piet; Alessandro Muzzi; Wendy Keijzers; Sara Comandi; Lisa De Tora; Mariagrazia Pizza; Rino Rappuoli; Diederik van de Beek; Arie van der Ende; Maurizio Comanducci
Journal:  PLoS One       Date:  2013-05-24       Impact factor: 3.240

8.  Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines.

Authors:  Monica Konar; Dan M Granoff; Peter T Beernink
Journal:  J Infect Dis       Date:  2013-05-28       Impact factor: 5.226

Review 9.  Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease.

Authors:  Lisa K McNeil; Robert J Zagursky; Shuo L Lin; Ellen Murphy; Gary W Zlotnick; Susan K Hoiseth; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

10.  Meningococcal vaccine antigen diversity in global databases.

Authors:  Carina Brehony; Dorothea M Hill; Jay Lucidarme; Ray Borrow; Martin C Maiden
Journal:  Euro Surveill       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.